Lebwohl, Mark
Strober, Bruce
Schrader, Amy
Li, Alvin H.
Eckmann, Thomas
Zhu, Baojin
Malatestinic, William N.
Birt, Julie
Feely, Meghan
Blauvelt, Andrew
Funding for this research was provided by:
Eli Lilly and Company
Article History
Accepted: 3 June 2024
First Online: 24 June 2024
Declarations
:
: This study was sponsored by CorEvitas, LLC, and the analysis was funded by Eli Lilly and Company. Access to study data was limited to CorEvitas, and CorEvitas statisticians completed all the analysis; all authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscription in the last two years by AbbVie, Amgen, Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly and Company, Genentech, GSK, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., and UCB S.A.
: ML: Employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune, Inc., Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. BS: Consultant (honoraria): AbbVie, Acelyrin, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Kangpu Pharmaceuticals, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Imagenebio, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Sun Pharma, Rapt, Regeneron, Sanofi-Genzyme,SG Cowen, Union Therapeutics, Ventyxbio, and vTv Therapeutics; Stock options: Connect Biopharma and Mindera Health; Speaker: AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme; Scientific co-director (consulting fee): CorEvitas Psoriasis Registry; Investigator: CorEvitas Psoriasis Registry; Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. AS, AHL, TE: CorEvitas employees; AHL: Eli Lilly stock. BZ, WNM, JB, MF: Eli Lilly employees/stock. AB: Speaker (received honoraria) for AbbVie, Eli Lilly and Company, Pfizer, and UCB; Scientific Adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and Clinical Study Investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx.
: Data are available from CorEvitas, LLC, through a commercial subscription agreement and are not publicly available. No additional data are available from authors.
: The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB; Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures.
: All patients in the registry were required to provide written informed consent and authorization prior to participating.
: The authors confirm contribution to the paper as follows: study conception or design: ML, AS, AHL, BZ, WNM, JB; data acquisition, analysis, or interpretation of results: ML, BS, AS, AHL, TE, BZ, WNM, JB, AB; manuscript drafting or critical revision for important content: ML, BS, AS, AHL, TE, BZ, WNM, JB, AB. All authors read and approved the final version.